Bai-Hu-Jia-Ren-Shen-Tang Decoction Reduces Fatty Liver by Activating AMP-Activated Protein Kinase in Vitro and in Vivo

Evidence-based Complementary and Alternative Medicine

Volumn 2015, Issue , 2015, Pages

  Liu, Hui Kang ^a,b   Hung, Tzu Min ^c   Huang, Hsiu Chen ^d   Lee, I Jung ^a   Chang, Chia Chuan ^e   Cheng, Jing Jy ^a   Lin, Lie Chwen ^a   Huang, Cheng ^a  

^a NATIONAL RESEARCH INSTITUTE OF CHINESE MEDICINE   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c E DA HOSPITAL   (Taiwan)

^d NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; BAI HU JIA REN SHEN TANG DECOCTION; CHINESE DRUG; CHOLESTEROL; GINSENOSIDE RG 3; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PALMITIC ACID; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; TUBULIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DYSLIPIDEMIA; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FATTY ACID OXIDATION; FATTY LIVER; GINSENG; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIPID STORAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; RICE; SIGNAL TRANSDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING;

EID: 84945546486     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2015/651734     Document Type: Article

References (39)

1. W. Dunn, R. Xu, D. L. Wingard et al., "Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study," The American Journal of Gastroenterology, vol. 103, no. 9, pp. 2263-2271, 2008.
2. C. Postic and J. Girard, "Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice," Journal of Clinical Investigation, vol. 118, no. 3, pp. 829-838, 2008.
3. H. C. Masuoka and N. Chalasani, "Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals," Annals of the New York Academy of Sciences, vol. 1281, no. 1, pp. 106-122, 2013.
4. B.W. Smith and L. A. Adams, "Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment," Nature Reviews Endocrinology, vol. 7, no. 8, pp. 456-465, 2011.
5. S. Parekh and F. A. Anania, "Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease," Gastroenterology, vol. 132, no. 6, pp. 2191-2207, 2007.
6. L. A. Adams and P. Angulo, "Treatment of non-alcoholic fatty liver disease," Postgraduate Medical Journal, vol. 82, no. 967, pp. 315-322, 2006.
7. V. Nobili, M. Manco, R. Devito et al., "Lifestyle intervention andantioxidant therapy inchildrenwithnonalcoholic fatty liver disease: a randomized, controlled trial," Hepatology, vol. 48, no. 1, pp. 119-128, 2008.
8. E. M. Brunt, "Histopathology of non-alcoholic fatty liver disease," Clinics in Liver Disease, vol. 13, no. 4, pp. 533-544, 2009.
9. C. Carter-Kent, L. M. Yerian, E.M. Brunt et al., "Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study," Hepatology, vol. 50, no. 4, pp. 1113-1120, 2009.
10. B. N. Reid, G. P. Ables, O. A. Otlivanchik et al., "Hepatic overexpression of hormone-sensitive lipase and adipose triglyceride lipase promotes fatty acid oxidation, stimulates direct release of free fatty acids, and ameliorates steatosis," Journal of Biological Chemistry, vol. 283, no. 19, pp. 13087-13099, 2008.
11. J. W. E. Jocken, D. Langin, E. Smit et al., "Adipose triglyceride lipase and hormone-sensitive lipase protein expression is decreased in the obese insulin-resistant state," The Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 6, pp. 2292-2299, 2007.
12. R. Zechner, P. C. Kienesberger, G. Haemmerle, R. Zimmermann, and A. Lass, "Adipose triglyceride lipase and the lipolytic catabolism of cellular fat stores," Journal of Lipid Research, vol. 50, no. 1, pp. 3-21, 2009.
13. B. B. Kahn, T. Alquier, D. Carling, and D. G. Hardie, "AMPactivated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism," Cell Metabolism, vol. 1, no. 1, pp. 15-25, 2005.
14. D. G. Hardie, "AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy," Nature Reviews Molecular Cell Biology, vol. 8, no. 10, pp. 774-785, 2007.
15. G. Zhou, R. Myers, Y. Li et al., "Role of AMP-activated protein kinase in mechanism of metformin action," Journal of Clinical Investigation, vol. 108, no. 8, pp. 1167-1174, 2001.
16. G. Schimmack, R. A. DeFronzo, and N. Musi, "AMP-activated protein kinase: role in metabolism and therapeutic implications," Diabetes, Obesity and Metabolism, vol. 8, no. 6, pp. 591-602, 2006.
17. B. Viollet, M. Foretz, B. Guigas et al., "Activation of AMPactivated protein kinase in the liver: a new strategy for themanagement of metabolic hepatic disorders," Journal of Physiology, vol. 574, no. 1, pp. 41-53, 2006.
18. C.-C. Chen, C.-Y. Hsiang, A.-N. Chiang, H.-Y. Lo, and C.-I. Li, "Peroxisome proliferator-activated receptor gamma transactivation- mediated potentiation of glucose uptake by Bai-Hu- Tang," Journal of Ethnopharmacology, vol. 118, no. 1, pp. 46-50, 2008.
19. C.-Y. Huang, Y.-T. Tsai, J.-N. Lai, and F.-L. Hsu, "Prescription pattern of Chinese herbal products for diabetes mellitus in Taiwan: a population-based study," Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 201329, 10 pages, 2013.
20. I. Kimura, N. Nakashima, Y. Sugihara, C. Fu-Jun, and M. Kimura, "The antihyperglycaemic blend effect of traditional Chinese medicine byakko-ka-ninjin-to on alloxan and diabetic KK-CA(y) mice," Phytotherapy Research, vol. 13, no. 6, pp. 484-488, 1999.
21. H. H. Aly, K. Watashi, M. Hijikata et al., "Serum-derived hepatitis C virus infectivity in interferon regulatory factor-7- suppressed human primary hepatocytes," Journal ofHepatology, vol. 46, no. 1, pp. 26-36, 2007.
22. K. Kobayashi, T. M. Forte, S. Taniguchi, B. Y. Ishida, K. Oka, and L. Chan, "The db/db mouse, a model for diabetic dyslipidemia: molecular characterization and effects of western diet feeding," Metabolism: Clinical and Experimental, vol. 49, no. 1, pp. 22-31, 2000.
23. S. P. Cousin, S. R. H�gl, C. E. Wrede, H. Kajio, M. G. Myers Jr., and C. J. Rhodes, "Free fatty acid-induced inhibition of glucose and insulin-like growth factor I-induced deoxyribonucleic acid synthesis in the pancreatic β-cell line INS-1," Endocrinology, vol. 142, no. 1, pp. 229-240, 2001.
24. J. L. Ram�rez-Zacar�as, F. Castro-Mu�ozledo, and W. Kuri- Harcuch, "Quantitation of adipose conversion and triglycerides by staining intracytoplasmic lipids with Oil red O," Histochemistry, vol. 97, no. 6, pp. 493-497, 1992.
25. E. G. Bligh and W. J. A. Dyer, "A rapid method of total lipid extraction and purification," Canadian Journal of Biochemistry and Physiology, vol. 37, no. 8, pp. 911-917, 1959.
26. V. Z�mb�, L. Simon-Szab�, P. Szel�nyi, �. Kereszturi, G. B�nhegyi, and M. Csala, "Lipotoxicity in the liver," World Journal of Hepatology, vol. 5, no. 10, pp. 550-557, 2013.
27. B. A. Neuschwander-Tetri and S. H. Caldwell, "Nonalcoholic steatohepatitis: summary of anAASLD single topic conference," Hepatology, vol. 37, no. 5, pp. 1202-1219, 2003.
28. D. G. Hardie, "AMPK and SNF1: snuffing out stress," Cell Metabolism, vol. 6, no. 5, pp. 339-340, 2007.
29. C.-L. Lin, H.-C. Huang, and J.-K. Lin, "Theaflavins attenuate hepatic lipid accumulation through activatingAMPKin human HepG2 cells," Journal of Lipid Research, vol. 48, no. 11, pp. 2334-2343, 2007.
30. J. D. McGarry and N. F. Brown, "The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis," European Journal of Biochemistry, vol. 244, no. 1, pp. 1-14, 1997.
31. L. Shen, Y. Xiong, D. Q.-H. Wang et al., "Ginsenoside Rb1 reduces fatty liver by activating AMP-activated protein kinase in obese rats," Journal of Lipid Research, vol. 54, no. 5, pp. 1430-1438, 2013.
32. S. Park, I. S. Ahn, D. Y. Kwon, B. S. Ko, and W. K. Jun, "Ginsenosides Rb1 and Rg1 suppress triglyceride accumulation in 3T3-L1 adipocytes and enhance beta-cell insulin secretion and viability in min6 cells viaPKA-dependent pathways," Bioscience, Biotechnology and Biochemistry, vol. 72, no. 11, pp. 2815-2823, 2008.
33. Y. Xiong, L. Shen, K. J. Liu et al., "Antiobesity and antihyperglycemic effects of ginsenoside Rb1 in rats," Diabetes, vol. 59, no. 10, pp. 2505-2512, 2010.
34. H.-C. Huang, C.-C. Chen, W.-C. Chang, M.-H. Tao, and C. Huang, "Entry of hepatitis B virus into immortalized human primary hepatocytes by clathrin-dependent endocytosis," Journal of Virology, vol. 86, no. 17, pp. 9443-9453, 2012.
35. Q. M. Anstee and R.D. Goldin, "Mousemodels in non-alcoholic fatty liver disease and steatohepatitis research," International Journal of Experimental Pathology, vol. 87, no. 1, pp. 1-16, 2006.
36. R. Burcelin, V. Crivelli, C. Perrin et al., "GLUT4, AMP kinase, but not the insulin receptor, are required for hepatoportal glucose sensor-stimulated muscle glucose utilization," The Journal of Clinical Investigation, vol. 111, no. 10, pp. 1555-1562, 2003.
37. A. Caimari, P. Oliver, and A. Palou, "Impairment of nutritional regulation of adipose triglyceride lipase expression with age," International Journal of Obesity, vol. 32, no. 8, pp. 1193-1200, 2008.
38. S. Nakamura, T. Takamura, N. Matsuzawa-Nagata et al., "Palmitate induces insulin resistance in H4IIEC3 hepatocytes through reactive oxygen species produced bymitochondria, "TheJournal of Biological Chemistry, vol. 284, no. 22, pp. 14809-14818, 2009.
39. S. Furukawa, T. Fujita, M. Shimabukuro et al., "Increased oxidative stress in obesity and its impact onmetabolic syndrome, "The Journal of Clinical Investigation, vol. 114, no. 12, pp. 1752-1761, 2004.